English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Healthcare & Pharm
康哲藥業(00867)獲得1類新藥長效抗IL-4Rα單抗MG-K10
Jan 26, 2025 13:14 HKT
康哲药业(00867)获得1类新药长效抗IL-4Rα单抗MG-K10
Jan 26, 2025 12:54 HKT
China Medical System (00867) Obtained Class 1 Innovative Drug Long-acting Anti-IL-4Ra Monoclonal Antibody MG-K10
Jan 24, 2025 23:00 HKT
Transforming Philippine Healthcare: The 2025 Philippine Hospital & Healthcare Digitalization Summit
Jan 20, 2025 16:59 HKT
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 09, 2025 21:34 HKT
康哲藥業獲得治療輕度至中度阿爾茨海默型癡呆症狀的新藥ZUNVEYL
Jan 09, 2025 11:17 HKT
康哲药业获得治疗轻度至中度阿尔茨海默型痴呆症状的新药ZUNVEYL
Jan 09, 2025 11:09 HKT
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 09, 2025 08:00 HKT
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 08, 2025 22:30 HKT
雲頂新耀引入新的國際投資者 首席執行官羅永慶及管理層堅定看好公司未來發展
Jan 08, 2025 17:04 HKT
云顶新耀引入新的国际投资者 首席执行官罗永庆及管理层坚定看好公司未来发展
Jan 08, 2025 16:59 HKT
Combat Holiday Stress and Protect Your Immunity with LAC This Christmas!
Jan 03, 2025 10:00 HKT
新版國家醫保藥品目錄落地 全球首個IgA腎病對因治療藥物耐賦康(R)納入報銷
Jan 02, 2025 10:52 HKT
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Jan 02, 2025 10:52 HKT
新版国家医保药品目录落地 全球首个IgA肾病对因治疗药物耐赋康(R)纳入报销
Jan 02, 2025 10:48 HKT
Global Humanitarian Gurudev Sri Sri Ravi Shankar to Give Keynote Address at United Nations World Meditation Day, Followed by Live Global Meditation
Dec 19, 2024 15:30 HKT
Everest Medicines Announces the First Prescription of VELSIPITY(R) in the Greater Bay Area
Dec 18, 2024 14:29 HKT
云顶新耀宣布伊曲莫德(VELSIPITY(R))大湾区内地首张处方在佛山正式落地
Dec 18, 2024 14:20 HKT
雲頂新耀宣佈伊曲莫德(VELSIPITY(R))大灣區內地首張處方在佛山正式落地
Dec 18, 2024 14:20 HKT
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY
Dec 17, 2024 10:58 HKT
Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: